Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CASI Pharma Acquires VCP/p97 Inhibitor for Myeloid Leukemia and MDS

publication date: Jul 21, 2023

CASI Pharmaceuticals, a China in-licensing company with operations in Beijing and Maryland, has acquired global rights to a novel VCP/p97 inhibitor from Cleave Therapeutics. CB-5339, which has completed a US Phase I trial in acute myeloid leukemia and myelodysplastic patients, is an oral small molecule valosin-containing protein (VCP)/p97 inhibitor, designed to disrupt protein homeostasis, DNA damage response and other cellular stress pathways. CASI will assume all responsibility for Cleave’s US IND for CB-5339 along with global intellectual property rights. Cleave also announced it is selling its preclinical assets to Eikon Therapeutics. More details....

Stock Symbol: (NASDAQ: CASI)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital